Travere Therapeutics, Inc. Earnings Per Share Diluted

• Travere Therapeutics, Inc. showed an increase of +92.9% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2013: $0.41 (loss) per share | Q3 2013: $0.71 (loss) per share | Q1 2014: $3.25 (loss) per share | Q2 2014: $0.77 (loss) per share | Q3 2014: $0.84 (loss) per share | Q4 2014: $1.10 (loss) per share | Q1 2015: $1.32 per share | Q2 2015: $0.73 (loss) per share | Q3 2015: $1.78 per share | Q4 2015: $0.14 (loss) per share | Q1 2016: $0.08 (loss) per share | Q2 2016: $0.37 (loss) per share | Q3 2016: $1.00 (loss) per share | Q4 2016: $0.39 (loss) per share | Q1 2017: $0.32 (loss) per share | Q2 2017: $0.34 (loss) per share | Q3 2017: $0.46 (loss) per share | Q4 2017: $0.55 (loss) per share | Q1 2018: $0.46 (loss) per share | Q2 2018: $0.56 (loss) per share | Q3 2018: $1.34 (loss) per share | Q4 2018: $0.18 (loss) per share | Q1 2019: $0.99 (loss) per share | Q1 2020: $0.02 per share | Q2 2020: $0.58 (loss) per share | Q3 2020: $0.44 (loss) per share | Q1 2021: $0.96 (loss) per share | Q2 2021: $0.64 (loss) per share | Q3 2021: $0.59 (loss) per share | Q1 2022: $1.20 (loss) per share | Q2 2022: $1.05 (loss) per share | Q3 2022: $1.09 (loss) per share | Q4 2022: $1.03 (loss) per share | Q1 2023: $1.27 (loss) per share | Q2 2023: $1.13 (loss) per share | Q3 2023: $1.97 per share | Q4 2023: $1.18 (loss) per share | Q1 2024: $1.76 (loss) per share | Q2 2024: $0.91 (loss) per share | Q3 2024: $0.70 (loss) per share | Q1 2025: $0.47 (loss) per share | Q2 2025: $0.14 (loss) per share | Q3 2025: $0.28 per share.
• Over the full 13 years of available data (2013 to 2025), Travere Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 88.1%.
• Historical annual values: Fiscal year 2025: $0.29 (loss) per share | Fiscal year 2024: $4.08 (loss) per share | Fiscal year 2023: $1.50 (loss) per share | Fiscal year 2022: $4.37 (loss) per share | Fiscal year 2021: $3.01 (loss) per share | Fiscal year 2020: $3.56 (loss) per share | Fiscal year 2019: $3.46 (loss) per share | Fiscal year 2018: $2.54 (loss) per share | Fiscal year 2017: $1.54 (loss) per share | Fiscal year 2016: $1.29 (loss) per share | Fiscal year 2015: $3.17 per share | Fiscal year 2014: $4.43 (loss) per share | Fiscal year 2013: $2.44 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026